<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613454</url>
  </required_header>
  <id_info>
    <org_study_id>R18-097</org_study_id>
    <nct_id>NCT03613454</nct_id>
  </id_info>
  <brief_title>Embolization in Splenic Trauma</brief_title>
  <acronym>ELSA</acronym>
  <official_title>Embolization in Splenic Trauma (ELSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, prospective, feasibility study to begin evaluating the efficacy, safety, and cost&#xD;
      of using either coils or vascular plugs (VPs) for proximal splenic artery embolization in the&#xD;
      setting of traumatic splenic injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Splenic preservation rates are improved for participants with high-grade splenic injuries&#xD;
      (defined as Grade III-V injuries by the American Association for the Surgery of Trauma (AAST)&#xD;
      guidelines) when non-operative management is supplemented by image-guided, trans-catheter&#xD;
      splenic artery embolization (SAE). SAE is currently the standard of care for hemodynamically&#xD;
      stable participants with high-grade splenic injuries. In proximal SAE (pSAE), the mid-splenic&#xD;
      artery is embolized between the origins of the dorsal pancreatic artery and pancreatica magna&#xD;
      artery with either VPs or coils. This reduces the intra-splenic arterial pressure which&#xD;
      allows the parenchyma time to heal. Splenic perfusion is maintained via a collateral pathway&#xD;
      consisting of flow from the splenic artery proximal to the site of embolization through the&#xD;
      smaller dorsal pancreatic artery to the transverse pancreatic artery to the pancreatica magna&#xD;
      artery which then delivers a slower, smaller amount of blood to the splenic artery distal to&#xD;
      the site of embolization. Additionally, collateral supply from the short gastric and&#xD;
      gastroepiploic arteries helps to protect the spleen from infarction and/or abscess formation.&#xD;
&#xD;
      pSAE is most often accomplished using either coils or VPs as the embolic agent, both of which&#xD;
      are FDA-approved and clinically-available. Coils have a long history of efficacy and safety&#xD;
      for embolization and are thus familiar embolic agents to most endovascular specialists.&#xD;
      Further, coils large enough to embolize the mid-splenic artery can be deployed through a&#xD;
      standard micro-catheter, which means they can be used in even the most tortuous splenic&#xD;
      arteries. However, multiple coils may need to be deployed in the same patient to achieve&#xD;
      hemostasis in the mid-splenic artery that may increase their overall cost, iodinated contrast&#xD;
      use, procedural time, and the radiation exposure to the participant and medical staff.&#xD;
      Additionally, given the high-flow nature of the splenic artery, even an appropriately sized&#xD;
      coil may migrate distally. A typical pSAE using coils will involve the deployment of one&#xD;
      helical coil followed by multiple packing coils until hemostasis is achieved. VPs attempt to&#xD;
      overcome the limitations of coils. For example, the deployment of a single VP can typically&#xD;
      provide hemostasis in the mid-splenic artery which theoretically reduces procedural time,&#xD;
      contrast load, and radiation exposure. Despite this, VPs are more expensive than coils on a&#xD;
      per unit basis and are usually less familiar devices to endovascular specialists. Another&#xD;
      drawback of VPs is that they cannot be deployed through a standard micro-catheter but rather&#xD;
      require the advancement of a larger, stiffer 0.035 inch system into the mid-splenic artery.&#xD;
      This may limit their use in very tortuous splenic arteries. Currently, the selection of&#xD;
      embolic agent for pSAE is primarily based on operator experience and preference. The embolic&#xD;
      efficacy, technical success, and cost of using coils compared to VPs has been evaluated in&#xD;
      other diseases; yet, to the best of our knowledge, these embolic agents have never been&#xD;
      compared for their use in pSAE, much less in a randomized, prospective fashion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were Enrolled Within 18 Months of Study Initiation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Embolization Success</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immediate Complications</measure>
    <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
    <description>This outcome will be measured by the number of intra-procedural complications and compared between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Splenic Salvage</measure>
    <time_frame>30 days after procedure</time_frame>
    <description>This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Exposure</measure>
    <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
    <description>The radiation exposure during the embolization procedure for each embolic will be measured and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Volume</measure>
    <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
    <description>The amount of contrast used during the procedure will be measured for each group and compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Trauma to the Spleen</condition>
  <arm_group>
    <arm_group_label>Splenic artery embolization with vascular embolic coils</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Splenic artery embolization with vascular embolic plugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Splenic artery embolization with vascular embolic coils</intervention_name>
    <description>Splenic artery embolization with vascular embolic coils</description>
    <arm_group_label>Splenic artery embolization with vascular embolic coils</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Splenic artery embolization with vascular embolic plugs</intervention_name>
    <description>Splenic artery embolization with vascular embolic plugs</description>
    <arm_group_label>Splenic artery embolization with vascular embolic plugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting to the University of Alabama at Birmingham (UAB) emergency room&#xD;
             requiring embolization of the splenic artery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Gunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>April Riddle</name>
      <address>
        <city>Harpersville</city>
        <state>Alabama</state>
        <zip>35078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Andrew J. Gunn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03613454/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
          <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
        </group>
        <group group_id="P2">
          <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
          <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
          <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
        </group>
        <group group_id="B2">
          <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
          <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="26" upper_limit="61"/>
                    <measurement group_id="B2" value="34" lower_limit="26" upper_limit="50"/>
                    <measurement group_id="B3" value="38" lower_limit="26" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Enrolled Within 18 Months of Study Initiation</title>
        <description>The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Enrolled Within 18 Months of Study Initiation</title>
          <description>The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Embolization Success</title>
        <description>This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Embolization Success</title>
          <description>This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immediate Complications</title>
        <description>This outcome will be measured by the number of intra-procedural complications and compared between the two groups</description>
        <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Complications</title>
          <description>This outcome will be measured by the number of intra-procedural complications and compared between the two groups</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Splenic Salvage</title>
        <description>This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.</description>
        <time_frame>30 days after procedure</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Splenic Salvage</title>
          <description>This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiation Exposure</title>
        <description>The radiation exposure during the embolization procedure for each embolic will be measured and compared.</description>
        <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Exposure</title>
          <description>The radiation exposure during the embolization procedure for each embolic will be measured and compared.</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>mGy</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" lower_limit="172" upper_limit="671"/>
                    <measurement group_id="O2" value="380" lower_limit="221" upper_limit="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Volume</title>
        <description>The amount of contrast used during the procedure will be measured for each group and compared.</description>
        <time_frame>During the embolization procedure, an average of 1 hour</time_frame>
        <population>Two participants dropped out due to protocol violation (invalid consent)</population>
        <group_list>
          <group group_id="O1">
            <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
            <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
          </group>
          <group group_id="O2">
            <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
            <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Volume</title>
          <description>The amount of contrast used during the procedure will be measured for each group and compared.</description>
          <population>Two participants dropped out due to protocol violation (invalid consent)</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="60"/>
                    <measurement group_id="O2" value="60" lower_limit="50" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Complications were recorded within 30 days from the procedure.</time_frame>
      <desc>Two participants dropped out due to protocol violation (invalid consent).</desc>
      <group_list>
        <group group_id="E1">
          <title>Splenic Artery Embolization With Vascular Embolic Coils</title>
          <description>Splenic artery embolization with vascular embolic coils: Splenic artery embolization with vascular embolic coils</description>
        </group>
        <group group_id="E2">
          <title>Splenic Artery Embolization With Vascular Embolic Plugs</title>
          <description>Splenic artery embolization with vascular embolic plugs: Splenic artery embolization with vascular embolic plugs</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coil migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coil migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. AJ Gunn</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-4850</phone>
      <email>agunn@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

